Background: People with opioid use disorder (OUD) are disproportionately burdened by HIV. The United States' Centers for Disease Control and Prevention (CDC) has issued guidelines for pre-exposure prophylaxis (PrEP) indication. We know little about PrEP for people receiving medication for OUD. The objective of this study is to report PrEP indication, awareness, and uptake in patients engaged in outpatient OUD treatment with buprenorphine.
Methods: Adult patients (n = 137) receiving buprenorphine for OUD at an outpatient substance use disorder treatment clinic completed a cross-sectional survey between July and September 2019. The study determined PrEP indication by 2017 CDC criteria. PrEP awareness and uptake were self-reported. The study assessed statistical differences in PrEP indicators by Pearson's χ and Fisher's exact.
Results: Nearly three-quarters (73.7%, n = 101) of the study sample met CDC criteria for PrEP-indication based on past-year risk behaviors. Ninety-five percent of these participants reported inconsistent condom use, 21.0% engaged in commercial sex, 9.0% shared injection equipment, 8.9% reported a recent bacterial STI, and 4.0% had an HIV+ sexual partner. Of PrEP indicated participants (n = 101), 19 had heard of PrEP prior to the survey, but only 1 participant reported past-year PrEP use.
Conclusions: Among a clinical population of people receiving buprenorphine for OUD, HIV risk behaviors were common, yet PrEP awareness and uptake were low. People engaged in treatment for OUD remain at high risk for HIV and are a priority population for PrEP. In light of the current opioid crisis, more research is needed to guide the integration of comprehensive HIV prevention into outpatient opioid treatment centers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630078 | PMC |
| http://dx.doi.org/10.1016/j.jsat.2021.108506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of HIV pre-exposure prophylaxis among men who have sex with men: low uptake and retention despite high-risk indications.
AIDS Care
January 2025
ByWard Family Health Team, Ottawa, Canada.
HIV PrEP is over 99% effective in preventing HIV when medication adherence is high. Despite this, uptake and retention in PrEP care remains less than optimal. We investigated whether gbMSM with objective risk factors for HIV who were automatically offered PrEP would have higher uptake and retention in PrEP care.
View Article and Find Full Text PDFPreference for Long-Acting HIV Prevention Methods Among Transgender Women Vulnerable to HIV in Eastern and Southern United States: Findings from the LITE Study.
AIDS Behav
December 2024
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 21205, USA.
HIV incidence among transgender women remains high and disproportionately impacts young, Black, and Latina transgender women. Data on preferred PrEP modalities among this population are limited. Participants in The LITE Cohort completed a survey module on PrEP modality preferences during 24-month study visits.
View Article and Find Full Text PDFRandomized controlled trial of a pilot PrEP linkage intervention for individuals leaving incarceration in a southern state: Design and baseline characteristics.
PLoS One
December 2024
Department of Health Behavior and Health Education, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Objective: We report baseline characteristics of a pilot intervention, PrEP-Link, which uses a community health worker (CHW) model to provide navigation to PrEP, the daily HIV preventative medication, and other medical and social services upon release from incarceration.
Trial Design And Methods: This pilot study uses a randomized controlled trial design. The control group receives enhanced standard of care, and the intervention receives enhanced standard of care plus personalized navigation services from the CHW for up to one year.
Brief Report: Gaps in HIV Preexposure Prophylaxis Acceptance: Findings From an Outpatient HIV Testing Service in Italy.
J Acquir Immune Defic Syndr
January 2025
Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy ; and.
Article Synopsis
- This study evaluated how acceptable HIV pre-exposure prophylaxis (PrEP) is among individuals eligible for it who received their first HIV test at a medical facility in Milan, Italy.
- Out of 2,627 people tested, 88.3% of those with negative results were men, and only 40% accepted PrEP; acceptance was significantly lower among women and non-Caucasians.
- The research highlighted a concerning trend: non-acceptance of PrEP was notably high among those diagnosed with sexually transmitted infections (STIs) during the testing process.
PrEP initiation and adherence among Black cisgender women in Mississippi: The role of HIV and PrEP stigma and social support.
Womens Health (Lond)
November 2024
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Article Synopsis
- Stigma and lack of social support create obstacles for HIV prevention among cisgender Black women, particularly in the U.S. South, leading to low rates of PrEP initiation and adherence.
- The study examined experiences with stigma and support among PrEP-naïve and experienced Black women in Mississippi through focus groups and interviews.
- Findings revealed themes of gendered racism, enacted and anticipated stigma regarding PrEP, strategies to cope with stigma, and the positive impact of social support on PrEP use and adherence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!